Introduction

Jubilee message

Nicotine and sympathetic neurotransmission

Markus Haass, Wolfgang Kübler

Effects of KT-362, a sarcolemmal and intracellular calcium antagonist, on calcium transients of cultured neonatal rat ventricular cells: A comparison with gallopamil and ryanodine

Youichi Tatsukawa, Makoto Arita

Heart rate and heart rate variability, a pharmacological target

Bernard Swynghedauw, Sylvain Jasson, Brigitte Chevalier, Jean Clairambault, Sandrine Hardouin, Christophe Heymes, Laurence Mangin, Pascale Manster, Claire Médigue, Jean-Marie Moalic, Nancy Thibault, François Carré

Clinical efficacy of propantheline bromide in neurocardiogenic syncope: Pharmacodynamic implications

John C. L. Yu, Ruey J. Sung

Current and newer approaches in the drug treatment of congestive heart failure

P. A. van Zwieten

Intropic agents in the treatment of heart failure: Despair or hope?

Shigetake Sasayama

Medical treatment of heart failure: The Canadian Cardiovascular Society's Consensus Conference revisited

Pascal Vantrimpont, Jean L. Rouleau

Acute and short-term effects of the nonpeptide endothelin-1 receptor antagonist bosentan in humans

Gabor Sütsch, Osmund Bertel, Wolfgang Kiowski

The case for low-dose aspirin for the prevention of myocardial infarction: But how low is low?

Werner Förster, James Roy Parratt

Nitrate tolerance, rebound, and their clinical relevance in stable angina pectoris, unstable angina, and heart failure

Udho Thadani

Hemostatic variables and ischemic cardiovascular disease: Do we need a concerted effort for more profitable future clinical investigations?

Giovanni Di Minno, Francesco Paolo Mancini, Maurizio Margaglione

The risk and cost-effective individual patient management: The challenge of a new generation of clinical trials

Attilio Maseri, Domenico Cianflone, Vincenzo Pasceri, Filippo Crea

Alternatives to mega-trials in cardiovascular disease

J. R. Hampton

Controversies in preconditioning

Jan Willem de Jong, Robert de Jonge, Andrea Marchesani, Maarten Janssen, Silvia Bradamante

Does protein kinase C play a pivotal role in the mechanisms of ischemic preconditioning?

Ben C. G. Gho, Yvonne E. G., Helmond Eskildsen, Sandra de Zeeuw, Jos M. J. Lamers, Pieter D. Verdouw

A head-to-head comparison of the cost effectiveness of HMG-CoA reductase inhibitors and fibrates in different types of primary hyperlipidemia

Sylvie Perreault, Vivian H. Hamilton, Frédéric Lavoie, Steven Grover

Endothelin, vascular hypertrophy, and hypertension

Clive Rosendorff

Effects of antihypertensive drugs on various aspects of renal function

Peter W. de Leeuw, Willem H. Birkenhäger